Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $62.67 USD
Change Today +1.50 / 2.45%
Volume 548.1K
ALKS On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 3:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Shane Martin Cooke

President,Alkermes plc
AgeTotal Calculated CompensationThis person is connected to 20 board members in 3 different organizations across 4 different industries.

See Board Relationships
53$4,646,966
As of Fiscal Year 2014

Background*

Mr. Shane Cooke has been the President of Alkermes Plc since September 16, 2011. Mr. Cooke served as an Executive Vice President of Elan Drug Technologies Inc. since May 2007 and served as its Head of Elan Drug Technologies (EDT). He served as an Executive Vice President and Head of Elan Drug Technologies (EDT) at Elan Corporation, plc from July 2001 to September 15, 2011 and from May 2007 to September 15, 2011. He served as the Chief Financial Officer of Elan Corporation, ...

Read Full Background

Corporate Headquarters*

Connaught House
Dublin, Co. Dublin 4

Ireland

Phone: 353 1 772 8000
Fax: --

Board Members Memberships*

Director
2012-Present
Director and Chairman of Audit Committee
2014-Present
Director, Member of Transactions Committee and Member of Audit Committee

Education*

Unknown/Other Education
University College Dublin

Other Affiliations*

Annual Compensation*

Salary$630,583
Total Annual Compensation$630,583

Stock Options*

Restricted Stock Awards$990,360
All Other Compensation$186,145
Exercisable Options371,250
Exercisable Options Value$15,614,450
Unexercisable Options343,750
Unexercisable Options Value$10,375,750
Total Value of Options$25,990,200
Total Number of Options715,000

Total Compensation*

Total Annual Cash Compensation$1,537,950
Total Short Term Compensation$630,583
Other Long Term Compensation$1,176,505
Total Calculated Compensation$4,646,966
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALKS:US $62.67 USD +1.50

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
James A. Schoeneck Chief Executive Officer, President and Director
DepoMed Inc.
$620.1K
George Frederick Wilkinson Chief Executive Officer, President and Director
Impax Laboratories Inc.
$552.5K
Kare Schultz Chief Executive Officer and President
H. Lundbeck A/S
--
Bruce C. Cozadd Co-Founder, Executive Chairman and Chief Executive Officer
Jazz Pharmaceuticals Public Limited Company
$830.0K
Daniel J. Abdun-Nabi Chief Executive Officer, President, Director, Member of Strategic Operations Committee and Member of Pricing Committee
Emergent BioSolutions, Inc.
$1.2M
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALKERMES PLC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.